BR9811989A - Tratamento de doenças imunes mediadas por células - Google Patents

Tratamento de doenças imunes mediadas por células

Info

Publication number
BR9811989A
BR9811989A BR9811989-3A BR9811989A BR9811989A BR 9811989 A BR9811989 A BR 9811989A BR 9811989 A BR9811989 A BR 9811989A BR 9811989 A BR9811989 A BR 9811989A
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
mediated immune
immune diseases
cell
treatment
Prior art date
Application number
BR9811989-3A
Other languages
English (en)
Other versions
BRPI9811989B8 (pt
BRPI9811989B1 (pt
Inventor
Werner Bollag
Fritz Ott
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8227266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9811989(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9811989A publication Critical patent/BR9811989A/pt
Publication of BRPI9811989B1 publication Critical patent/BRPI9811989B1/pt
Publication of BRPI9811989B8 publication Critical patent/BRPI9811989B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Patente de Invenção: <B>"TRATAMENTO DE DOENçAS IMUNES MEDIADAS POR CéLULAS"<D>. Foi visto que ácido 9-cis retinóico e sais farmaceuticamente aceitáveis e ésteres hidrolizáveis farmaceuticamente aceitáveis do mesmo, 9-cis retinal e acetais farmaceuticamente aceitáveis do mesmo, 9-cis retinol e ésteres hidrolizáveis farmaceuticamente aceitáveis do mesmo bem como metabólicos de ácido 9-cis retinóico são eficazes no tratamento de doenças imunes mediadas por células auxiliares T do tipo 1 em doses bem toleradas. Preferencialmente, o ingrediente ativo é formulado como um medicamento para administração oral ou tópica.
BRPI9811989A 1997-08-23 1998-08-18 uso do ácido 9-cis retinóico para a fabricação de um medicamento BRPI9811989B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97114651A EP0908179A1 (en) 1997-08-23 1997-08-23 Treatment of cell-mediated immune diseases
PCT/EP1998/005236 WO1999009969A1 (en) 1997-08-23 1998-08-18 Treatment of cell-mediated immune diseases

Publications (3)

Publication Number Publication Date
BR9811989A true BR9811989A (pt) 2000-09-05
BRPI9811989B1 BRPI9811989B1 (pt) 2015-12-15
BRPI9811989B8 BRPI9811989B8 (pt) 2021-05-25

Family

ID=8227266

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9811989A BRPI9811989B8 (pt) 1997-08-23 1998-08-18 uso do ácido 9-cis retinóico para a fabricação de um medicamento

Country Status (18)

Country Link
US (2) US6589989B1 (pt)
EP (2) EP0908179A1 (pt)
JP (1) JP3522220B2 (pt)
KR (1) KR100596260B1 (pt)
CN (1) CN1136845C (pt)
AT (1) ATE259224T1 (pt)
AU (1) AU739440B2 (pt)
BR (1) BRPI9811989B8 (pt)
CA (1) CA2301907C (pt)
DE (1) DE69821624T2 (pt)
DK (1) DK1007020T3 (pt)
ES (1) ES2214729T3 (pt)
NO (1) NO327141B1 (pt)
NZ (1) NZ502812A (pt)
PT (1) PT1007020E (pt)
RU (1) RU2238083C2 (pt)
TR (1) TR200000488T2 (pt)
WO (1) WO1999009969A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541469B2 (en) * 1997-08-23 2013-09-24 Glaxo Group Limited Treatment of cell-mediated immune diseases
US20020031539A1 (en) * 2000-08-30 2002-03-14 The Brigham And Women's Hospital, Inc. Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma
DE10255861A1 (de) * 2002-11-29 2004-06-17 Axxima Pharmaceuticals Ag Gegen Hepatitis C-Virusinfektionen nützliche Verbindungen und Substanzen
FR2834216B1 (fr) * 2001-12-27 2004-04-30 Pharmascience Lab Composition cosmetique ou pharmaceutique comprenant au moins une oxazoline pour inhiber la migration des cellules de langerhans, et ses utilisations
JP2004020220A (ja) * 2002-06-12 2004-01-22 Pioneer Electronic Corp 通信システム及び方法、通信端末装置、通信センタ装置、並びにコンピュータプログラム
TW579640B (en) * 2002-10-23 2004-03-11 Veutron Corp Light gathering device of scanner
EP1527774A1 (en) 2003-11-03 2005-05-04 Basilea Pharmaceutica AG New formulation for retinoid-containing soft gelatin capsules
EP2327401A3 (en) 2003-03-14 2011-10-19 University of Washington Retinoid Replacements and Opsin Agonists and Methods for the Use Thereof
CA2520018C (en) 2003-04-11 2011-01-04 F. Hoffmann-La Roche Ag Process for the production of 9-cis retinoic acid
US7122751B1 (en) * 2004-01-16 2006-10-17 Cobalt Flux Switch apparatus
WO2005070413A1 (ja) * 2004-01-23 2005-08-04 Japan Science And Technology Agency レチノイン酸を含有する糖尿病治療薬
AU2015207903B2 (en) * 2004-06-18 2017-08-17 University Of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders
WO2006002097A2 (en) 2004-06-18 2006-01-05 University Of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders
AU2012216808B2 (en) * 2004-06-18 2015-04-30 University Of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders
EP2286807A3 (en) * 2005-09-09 2012-08-29 Kemphys Ltd. Medicament for preventive and/or therapeutic treatment of adhesion of bowel
WO2009102418A1 (en) 2008-02-11 2009-08-20 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
US8580278B2 (en) * 2009-06-03 2013-11-12 Trustees Of Dartmouth College Nutraceutical composition and methods for preventing or treating multiple sclerosis
US20120178806A1 (en) 2009-09-15 2012-07-12 Qlt Inc. Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
KR20180043846A (ko) 2010-04-19 2018-04-30 노벨리언 테라퓨틱스 인코포레이티드 내인성 레티노이드 결핍과 연관된 시각 장애의 치료 또는 완화를 위한 치료 요법 및 방법
WO2012125724A1 (en) 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of proliferative disorders
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
CN102247348A (zh) * 2011-05-23 2011-11-23 天津拓飞生物科技有限公司 9-顺式维甲酸在制备治疗糖尿病皮肤溃疡的药物中的应用
US9439884B2 (en) 2011-05-26 2016-09-13 Beth Israel Deaconess Medical Center, Inc. Methods for the treatment of immune disorders
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital LIPID-CONTAINING PSA COMPOSITIONS, METHODS OF ISOLATION AND METHODS OF USING SAME
CA2865935C (en) 2012-03-01 2021-12-14 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
CA2875798A1 (en) 2012-06-07 2013-12-12 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of pin1
US9221854B2 (en) 2012-08-17 2015-12-29 Basf Se Isomerization of olefinic compounds
JP6461792B2 (ja) 2012-08-17 2019-01-30 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ オレフィン化合物の異性化
US20150202172A1 (en) * 2014-01-22 2015-07-23 Glaxo Group Limited Novel method of use
WO2016011265A2 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Biomarkers for pin1-associated disorders
US9968579B2 (en) 2014-07-17 2018-05-15 Beth Isreal Deaconess Medical Center, Inc. ATRA for modulating Pin1 activity and stability
WO2016145186A1 (en) 2015-03-12 2016-09-15 Beth Israel Deaconess Medical Center, Inc. Enhanced atra-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
EP3337321A4 (en) 2015-08-19 2019-07-17 President and Fellows of Harvard College LIPIDED PSA COMPOSITIONS AND METHOD
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
CN113499335B (zh) * 2021-07-13 2023-06-20 中国人民解放军军事科学院军事医学研究院 一种靶向自噬融合治疗神经退行性疾病的药物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525635A (en) * 1986-02-04 1996-06-11 Moberg; Sven Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
US5093360A (en) * 1989-04-07 1992-03-03 Yu Ruey J Retinal, derivatives and their therapeutic use
US5057501A (en) * 1990-03-13 1991-10-15 Dermatologic Research Corporation Methods for treatment of papulosquamous and eczematous diseases
US5932622A (en) * 1991-12-18 1999-08-03 The Salk Institute For Biological Studies Method for in vivo modulation of non-malignant skin-related processes with 9-cis-retinoic acid
KR100274101B1 (ko) 1992-01-22 2000-12-15 프리돌린 클라우스너, 롤란드 비. 보레르 9-시스 레틴산을 함유하는 약제학적 조성물
US5750570A (en) * 1992-03-31 1998-05-12 The Regents Of The University Of Michigan Method of treatment of hyperpigmentation in black skin with retinoic acid and method of lightening black skin with retinoic acid
CA2093577C (en) 1992-05-07 2006-01-03 Michael Klaus Alkyl or alkoxy substituted s-heterocyclic retinoids
TW272187B (pt) * 1992-05-20 1996-03-11 Hoffmann La Roche
WO1994022818A1 (en) * 1993-04-05 1994-10-13 Pfizer Inc. Method for the preparation of 9-cis retinoic acid
US5457129A (en) * 1993-05-17 1995-10-10 Research Development Foundation Inhibition of nitric oxide production by retinoic acid
FR2717686B1 (fr) * 1994-03-22 1996-06-28 Fabre Pierre Cosmetique Composition dermo-cosmétologique et procédé de préparation.
DE4415204A1 (de) * 1994-04-30 1995-11-02 Carl Heinrich Dr Weischer Neue Retinol (Vitamin A) -Derivate, deren Herstellung und Verwendung als Arzneimittel und Kosmetika
FR2728790B1 (fr) * 1994-12-29 1997-01-24 Cird Galderma Composition modulant l'apoptose comprenant du methonial ou tout facteur influencant le taux intracellulaire de methonial
US5721103A (en) * 1994-12-30 1998-02-24 Ligand Pharmaceuticals Incorporated Trienoic retinoid compounds and methods
US5837728A (en) * 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
FR2735367B1 (fr) * 1995-06-19 1997-07-18 Cird Galderma Utilisation de ligands specifiques des recepteurs rxrs
FR2752734B1 (fr) * 1996-09-02 1998-11-06 Cird Galderma Utilisation de retinoides pour la preparation d'un medicament destine a traiter les affections liees a une surexpression de vegf
US5994081A (en) * 1998-04-27 1999-11-30 Incyte Pharamaceuticals, Inc. Human keratins
US20030105031A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Methods for the treatment of skin disorders

Also Published As

Publication number Publication date
NO327141B1 (no) 2009-05-04
AU9435698A (en) 1999-03-16
EP1007020B1 (en) 2004-02-11
DE69821624D1 (de) 2004-03-18
CA2301907A1 (en) 1999-03-04
CN1268886A (zh) 2000-10-04
RU2238083C2 (ru) 2004-10-20
NO20000870D0 (no) 2000-02-22
ES2214729T3 (es) 2004-09-16
JP3522220B2 (ja) 2004-04-26
TR200000488T2 (tr) 2000-07-21
EP0908179A1 (en) 1999-04-14
WO1999009969A1 (en) 1999-03-04
ATE259224T1 (de) 2004-02-15
JP2003526595A (ja) 2003-09-09
CA2301907C (en) 2009-02-10
BRPI9811989B8 (pt) 2021-05-25
CN1136845C (zh) 2004-02-04
DE69821624T2 (de) 2004-09-23
KR20010023186A (ko) 2001-03-26
NZ502812A (en) 2002-05-31
NO20000870L (no) 2000-02-22
AU739440B2 (en) 2001-10-11
US20040039056A1 (en) 2004-02-26
EP1007020A1 (en) 2000-06-14
DK1007020T3 (da) 2004-06-07
KR100596260B1 (ko) 2006-07-03
PT1007020E (pt) 2004-05-31
BRPI9811989B1 (pt) 2015-12-15
US6589989B1 (en) 2003-07-08

Similar Documents

Publication Publication Date Title
BR9811989A (pt) Tratamento de doenças imunes mediadas por células
NO920740D0 (no) Doseringsform for oral administrering av hypoglykemisk glipizid
ATE67677T1 (de) Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten.
ID24901A (id) Metode pengobatan keadaan terkoagulasi tinggi atau defisiensi protein c yang diperoleh
GEP20002298B (en) Benzimidazole Derivatives, Method of Their Production, Pharmaceutical Composition Containing the Same and Method for Its Treatment
CA2503810A1 (en) Therapeutic agent for fibromyalgia
CA2158036A1 (en) 3,4-Diarylchromans for Treatment of Dermatitis
KR20100126367A (ko) 사마귀, 우종 및 건선성 플라크의 치료를 위한 생귀나린, 첼레리트린 또는 첼리도닌을 포함하는 제제
EP0414772A4 (en) Method for treating acne
US4469702A (en) Analgesic composition and use thereof to ameliorate deep and intractable pain
KR910005858A (ko) 지방산 요법
CA2180178A1 (en) Use of 2,3-diaryl-1-benzopyran derivatives for the manufacture of a medicament in the treatment and prevention of bone loss and osteoporosis
JPH04243825A (ja) 色素沈着症治療剤
CA2313618A1 (en) Transmucosal formulations of levosimendan
WO2001074396A8 (en) Composition and method for promoting oral health
EP0294914A3 (en) Nedocromil for the treatment of dermatological disorders
US5945119A (en) Therapeutic preparations containing caesium ions
JP2004513149A (ja) 炎症の治療法
MY114716A (en) Prophylactic and/or therapeutic treatment of dyspeptic symptoms
CA2474703A1 (en) Therapeutic agent of glaucoma comprising bunazosin and prostaglandins
EP0468122A1 (fr) Composition thérapeutique à base de polihexanide pour le traitement des manifestations cutanées, oculaires et génitales de l&#39;herpès
CA2373611C (en) Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
AU1400895A (en) 2,3-diaryl-1-benzopyrans for treating dermatitis
US4218445A (en) N,N&#39;Dibenzylethylenediamine-diacetylsalicylate, a novel chemotherapeutic agent for pain relief by external application
IT1184287B (it) Composizione per la preparazione di un medicamento da usare per la cura della piorrea alveolare

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: BASILEA PHARMACEUTICA AG (CH)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 31/07, A61P 37/02, C07C 403/20

Ipc: A61K 31/07 (2008.01), A61P 37/02 (2008.01), C07C 4

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: REFERENTE A RPI 1932 DE 15/01/2008.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: REFERENTE A RPI 1970 DE 07/10/2008.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA ( ART. 8O COMBINADO COM ART. 13 DA LPI ), NAO APRESENTA SUFICIENCIA DESCRITIVA ( ART. 24 DA LPI )

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25A Requested transfer of rights approved

Owner name: GLAXO GROUP LIMITED (GB)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/12/2015, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/08/1998 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 18/08/2018